1. Introduction {#sec1}
===============

Cholangiocarcinoma (CCA) is one of the highly aggressive malignant tumors that arise from the cholangiocytes lining biliary trees \[[@B1]\]. The incidence and mortality of the disease continue to increase worldwide, and the highest incidence has been observed in the Southeast Asia, especially in Thailand \[[@B2], [@B3]\]. The prognosis of this malignancy is poor due to its silent clinical characteristics, difficulties in early diagnosis, and limited therapeutic measures. At present, radiotherapy and chemotherapy do not significantly improve the survival rate, while the resection of detected tumors at the early stage offers the best curative treatment \[[@B4]\]. Clinical presentations of most CCA patients include biliary tract obstruction; however, many cases of benign biliary tract diseases (BBTDs) are also presented with similar clinical symptoms \[[@B5]\]. Differences in the treatment and prognosis between CCA and BBTDs urge us a need to identify accurate tumor biomarkers that can differentially diagnose the CCA from BBTDs. As CCA typically grows along the bile duct without protruding outward as a forming mass, therefore current imaging techniques including ultrasound, computed tomography (CT), and magnetic resonance imaging (MRI) are not efficient to reveal this lesion \[[@B6]\]. Laboratory assessments for CCA are often not sensitive, nor specific enough. Distinguishing between benign and malignant causes of biliary tract obstruction based on biopsies is rather difficult and usually inadequate to provide an accurate measure. Currently, determination of the serum marker carbohydrate antigen 19-9 (CA19-9) concentration is routinely applied in most laboratories for CCA detection. However, a wide range of sensitivity (50--90%) and specificity (54--98%) of this biomarker for CAA has been reported \[[@B7]--[@B9]\], and the elevated serum CA19-9 has also been observed in patients with BBTDs \[[@B10], [@B11]\]; therefore, the use of CA19-9 for differentiating CCA and BBTDs is not reliable. Other serum markers including carcinoembryogenic antigen (CEA) and cancer antigen 125 (CA125) have also been used for detecting CCA, but these markers are not satisfactory for CCA detection due to low specificity and sensitivity for screening \[[@B12]--[@B14]\]. Hence, identification of new tumor markers in the serum would be beneficial in the clinical management of this disease.

In recent years, quantitative proteomics has gained considerable attention and investment in order to identify diagnostic biomarkers for several diseases, including a variety of cancers \[[@B15]\]. In the present study, the proteome of serum samples from CCA patients were quantitatively compared with that of patients with BBTDs, who have shared many molecular and imaging features with CCA. A large-scale quantitative global protein profiling of serum coupled with bioinformatic analyses would identify a proteomic signature for effectively differentiating CCA from BBTDs. Patterns of differentially serum protein expression between CCA and BBTD patients were exploited for development of diagnostic or prognostic tool for this type of cancer.

2. Methods {#sec2}
==========

2.1. Serum Samples {#sec2.1}
------------------

Serum samples were collected from obstructive jaundice patients who underwent endoscopic retrograde cholangiography (ERCP) or biliary tract surgery at Rajavithi Hospital. The use of human materials was approved by the research ethics committee of Rajavithi Hospital. Seventeen patients with BBTDs and 19 CCA patients were enrolled in this study. The diagnosis of CCA was carried out using one of the following criteria: (i) tissue biopsy; (ii) cytology plus radiological (CT scan or MRI) and clinical observation to identify tumor progression at a follow-up of at least two months. Serum samples from these patients were separated by centrifugation and stored at −80°C within 1 h. The biochemical determinations of serum markers, including CEA and CA19-9, were performed using routine automated methods in the Pathological Laboratory at Rajavithi Hospital.

2.2. Sample Preparation, Electrophoresis, and Trypsin Digestion {#sec2.2}
---------------------------------------------------------------

Samples were treated with protease inhibitor cocktail and protein extraction from serum was carried out in lysis buffer containing 8 M urea and 10 mM dithiothreitol (DTT). Protein concentration was determined using Bradford protein assay with bovine serum albumin as a standard. Fifty micrograms of total serum proteins were resolved on 12.5% SDS-PAGE. The gel was then fixed for 30 min in a fixing solution containing 50% methanol, 12% acetic acid, and 0.05% formaldehyde, washed twice for 20 min in 35% ethanol, and then sensitized in 0.02% (w/v) sodium thiosulfate for 2 min with mild agitation. After washing twice for 5 min each with deionized water, the gel was then stained with 0.2% (w/v) silver nitrate for 20 min and washed twice prior to the detection in a developing solution (6% (w/v) sodium carbonate, 0.02% (w/v) sodium thiosulfate and 0.05% formalin). The staining was stopped by incubation in 1.5% Na~2~ EDTA solution for 20 min. Finally, the stained gel was washed three times for 5 min each with deionized water. The gel was scanned using a GS-710 scanner (Bio-Rad, Benicia, CA) before being stored in 0.1% acetic acid until in-gel tryptic digestion.

The gel lanes were divided into 5 fractions according to the standard protein markers and then subdivided into 15 ranges. Each gel range was chopped into pieces (1 mm^3^/piece), which were dehydrated in 100% acetonitrile (ACN) for 5 min with agitation and dried at room temperature for 15 min. Subsequently, the cysteine residues were blocked with 10 mM DTT in 10 mM NH~4~HCO~3~ for 1 h at room temperature and alkylated with 100 mM iodoacetamide in 10 mM NH~4~HCO~3~ for 1 h at room temperature in the dark. The gel pieces were dehydrated twice in 100% ACN for 5 min and then were incubated with 0.20 *μ*g trypsin in 50% ACN/10 mM NH~4~HCO~3~ for 20 min. Purified peptide fractions were dried and reconstituted in 2% ACN and 0.1% formic acid for subsequent LC-MS/MS.

2.3. Liquid Chromatography-Tandem Mass Spectrometry (LC/MS-MS) {#sec2.3}
--------------------------------------------------------------

The LC-MS/MS analysis was carried out using a Waters nanoACQUITY ultra performance liquid chromatography coupled with a SYNAPT HDMS mass spectrometer. A 5-*μ*L aliquot of peptide fractions was injected using a built-in nanoACQUITY auto sampler onto a Symmetry C18 trapping column (200 *μ*m × 180 mm, 5 *μ*m particle size; Waters) at 10 *μ*L/min flow rate for on-line desalting and then separated on a C-18 RP nano-BEH column (75 *μ*m id × 200 mm, 1.7 *μ*m particle size, Waters) and eluted in a 30 min gradient of 2% to 40% ACN in 0.1% formic acid (FA) at 350 nL/min, followed by a 10-min ramping to 80% ACN-0.1% FA and a 5-min holding at 80% ACN-0.1% FA. The column was reequilibrated with 2% ACN-0.1% FA for 20 min prior to the next run. The MS nanoion source contained a 10-*μ*m analyte emitter (New Objective, Woburn, MA) and an additional 20-*μ*m reference sprayer through which a solution of 200 fmol/*μ*L Glu Fibrinopeptide B (Glufib) in 25% ACN-0.1% FA was constantly infused at 200 nL/min for external lock mass correction at 30 s intervals. For all measurements, the MS instrument was operated in V mode (at 10,000 resolution) with positive nanoES ion mode. The instrument was tuned and calibrated by infusion of 200-fmol/*μ*L Glufib and set up for a spray voltage at 2.7 kV and sample cone voltage at 45 eV. The spectral acquisition time was 0.6 sec. In MS expression mode, low energy of trap was set at a constant collision energy of 6 V. In elevated energy of MS expression mode, the collision energy of trap was ramped from 15 to 40 V during each 0.6-s data collection cycle with one complete cycle of low and elevated energy. In transfer collision energy control, 4 V and 7 V were set for low and high energy, respectively. The quadrupole mass analyzer was adjusted such that ions from m/z 200 to 1990 were efficiently transmitted.

2.4. Data Processing, Protein Identification, and Data Analysis {#sec2.4}
---------------------------------------------------------------

Continuum LC-MS data were processed using ProteinLynx Global Server version 2.4 (Waters) for ion detection, clustering, and mass correction. Protein identification was performed with the embedded ion accounting algorithm against NCBI human protein database with the minimum cutoffs of two peptides/proteins. The relative quantitation ratios were log~2~-transformed, processed with median normalization for each sample and rank normalization across the data set. The data were subjected to a 6-fold cross-validation. A differentially expressed (DE) protein was defined as having a *P* value of \<0.01, based on *t*-distribution with Welch approximation, in all data sets in the fold validation. The visualization and statistical analyses were performed using the MultiExperiment Viewer (MeV) in the TM4 suite software \[[@B16]\]. Other information including protein categorization and biological function was analyzed according to protein analysis through evolutionary relationships (Panther) protein classification \[[@B17]\]. Known and predicted functional interaction networks of identified proteins were derived from the STRING database version 9.1 \[[@B18]\].

2.5. Statistical Analysis {#sec2.5}
-------------------------

Comparisons between the quantitative variables were performed using either the Mann-Whitney *U* or Student\'s *t*-test, where appropriate. Qualitative variables were reported as counts, and comparisons between independent groups were performed using Pearson Chi-squared tests. *P* values of less than 0.05 were considered significant.

3. Results {#sec3}
==========

3.1. Patient Characteristics {#sec3.1}
----------------------------

A total of 36 subjects were included in this serum proteome study, of which 17 were diagnosed as having BBTDs and 19 were diagnosed as having CCA. The BBTD cases included intrahepatic duct stones, common bile duct stones, and benign bile duct strictures. The CCA cases included perihilar cholangiocarcinoma, intrahepatic cholangiocarcinoma, and middle and distal common bile duct cancer. The clinical characteristics of the patients in this study are shown in [Table 1](#tab1){ref-type="table"}. No statistically significant differences were found among the data of the BBTD patients and those with CCA regarding gender, age, and CEA. Although the level of CA19-9 in the serum of patients with CCA was significantly higher when compared to the control patients, the range of detection in both groups was exactly the same (0.60--10000).

3.2. Serum Proteome Profiling {#sec3.2}
-----------------------------

An overview of the experimental strategy conducted in this study is shown in [Figure 1](#fig1){ref-type="fig"}. The proteome of serum samples from CCA patients was compared with the serum proteome of the BBTD controls in order to identify the proteins in serum, in particular those that are secreted or leaked from tissues including potential differential protein biomarkers from tumor cells. A total of 951 proteins were identified in all samples. Among these, the ones with altered expression levels in the serum of CCA patients compared to those of BBTD patients were identified. To reduce the effect of biological and experimental variations and the possibility of false-positive protein identification, 6-fold cross-validations were performed. In each fold, BBTD and CCA samples were randomly split into a training set (30 cases with 13--15 BBTD and 15--17 CCA) and an independent validation set (6 cases with 2--4 BBTD and 2--4 CCA). Only proteins identified and quantifiable in all folds in cross-validation were further analyzed, allowing for stringent and sensitive protein identification and quantification of differential proteins.

3.3. Identification of Differentially Expressed Proteins between CCA and BBTDs {#sec3.3}
------------------------------------------------------------------------------

Applying a *P* value cutoff of \<0.01 yielded a total of 94 candidate proteins, with 32 of them up and 62 down in observed abundance for the serum samples from CCA patients comparing to the BBTD controls ([Table 2](#tab2){ref-type="table"} and [Figure 2(a)](#fig2){ref-type="fig"}). We also tested the discriminatory power of these differentially expressed proteins using unsupervised hierarchical clustering. As shown in [Figure 2(c)](#fig2){ref-type="fig"}, the spectral counts for these proteins resulted in near complete separation of the CCA cases from the BBTD control cases with only two exceptions where BBTD cases were clustered with the CCA samples. However, the PCA scores plot based on the normalized data of serum samples showed a clear separation between the CCA patients and BBTD controls ([Figure 2(b)](#fig2){ref-type="fig"}).

The Panther classification system was used to identify the functional attributes of the 94 potential CCA-selective proteins. The analysis of the abundance of each functional category revealed substantial differences in CCA serum proteome compared to the BBTD serum proteome. The number of each functional class of differentially expressed proteins is schematically depicted in [Figure 3](#fig3){ref-type="fig"}. The analysis revealed significant enrichment of proteins related to a number of various biological functions such as cell adhesion molecules, cytoskeletal proteins, defense/immunity proteins, enzymes and the modulators, extracellular matrix proteins, membrane traffic proteins, nucleic acid-binding proteins, receptors, signaling molecules, structural proteins, transcription factors, transfer/carrier proteins, and transporters. To gain an overview of the biological interaction among the identified proteins, we also constructed the protein-protein functional networks using String database ([Figure 4](#fig4){ref-type="fig"}). The protein network analysis provides us a clearer view of a complex framework of proteins that might result in the differences in CCA and BBTDs.

To determine the distinguishing performance of the top five differentially expressed proteins in terms of fold-change, the comparison of the averaged log~2~ folds of family with sequence similarity 19 (chemokine (C-C motif)-like), member A5 (FAM19A5) protein, KIAA0321 protein, melanoma-associated antigen D4 (MAGED4B), RB-associated KRAB zinc finger protein (RBAK), and regulator of nonsense transcripts 3B (UPF3B), between CCA and BBTD cases from all cross-validation cohorts was shown in [Figure 5](#fig5){ref-type="fig"}. However, due to the limited resources and the lack of availability of an independent validation set, the diagnostic relevance of such molecules for CCA requires further investigation.

4. Discussion {#sec4}
=============

CCA is the second most prevalent primary hepatobiliary malignancy and represents about 3% of all gastrointestinal cancers \[[@B1]\]. It is associated with inflammatory conditions in the biliary system, and patients with risk factors such as primary sclerosing cholangitis and liver fluke infestations have a higher risk for CCA development \[[@B1]--[@B3]\]. The generally late clinical presentation of CCA results in a high mortality. At present, the most commonly studied and routinely used serum biomarkers for detecting CCA include CEA and CA19-9 \[[@B6]\]. However, they are nonspecific to CCA and can be elevated in the setting of other gastrointestinal malignancies or other benign conditions, such as cholangitis, cirrhosis, and hepatolithiasis \[[@B7]--[@B14]\]. Based on the results in this study, both CEA and CA19-9 could not also distinguish the patients with CCA and BBTDs in our sample cohort as both appeared to be nonspecific for either case. Hence, there is an urgent need for new diagnostic targets. In this study, we evaluated the differential proteome in the serum between the BBTD controls and CCA patients and identified potential biomarker panels to aid in the diagnosis of these common liver diseases.

Total proteins were retrieved from the whole serum without the depletion of high abundant proteins due to the fact that additional steps may not help enrich the level of low abundant proteins and may reduce reproducibility from one sample to the others \[[@B19]\]. Among the identified proteins, we found that a number of them had previously been described in the context of CCA, confirming the validity of our quantitative proteomic approach. These included overexpression of MAGED4 \[[@B20]\] and DNA mismatch repair protein (MLH1) \[[@B21], [@B22]\], downregulation of albumin (ALB) \[[@B20]\], apolipoprotein B (APOB) \[[@B20]\], apolipoprotein A-II (APOA2) \[[@B20]\], and interalpha (globulin) inhibitor H1 (ITIH1) \[[@B20], [@B23]\]. Expression of serum alpha 1-macroglobulin (A2M) was found to be significantly higher in BBTD compared to CCA patients. Consistently, it has also been reported that the serum A2M increased in patients with liver malignancies including CCA but markedly elevated in hepatic cirrhosis \[[@B24]\]. Fibronectin 1 (FN1) in serum of CCA patients seemed to be lower than that of BBTD patients. Biliary FN1 has been reported as a differential biomarker of benign and malignant diseases \[[@B25]\]. Similarly, serum plasminogen (PLG) of CCA cases was significantly lower than that of BBTD controls. PLG in malignant livers including CCA has been demonstrated to be lower than that of the cirrhosis patients \[[@B26]\]. Other serum proteins were also found differentially expressed between CCA and BBTD including angiotensinogen (AGT), ADAM metallopeptidase with thrombospondin type 1 motif 3 (ADAMTS3), hemoglobin, zeta (HBZ), keratin-1 (KRT1), keratin-10 (KRT10), and serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), and member 1 (SERPINA1). However, the validation of these identified proteins is needed in order to determine if they can be clinically useful as differential biomarkers for CCA and BBTD.

The top five proteins which exhibited the maximal fold change between CCA and BBTD consisted of FAM19A5, MAGED4B, KIAA0321, RBAK, and UPF3B. FAM19A5 belongs to the TAFA family of small secreted proteins, which are brain-specific and distantly related to MIP-1 alpha, a member of the CC-chemokine family \[[@B27]\]. This family of proteins has been postulated to function as brain-specific chemokines or neurokines that act as regulators of immune and nervous cells, although the association of this protein and CCA pathogenesis has yet to be evaluated. For MAGED4B, its overexpression has been linked to malignant tumors and poor patient outcome in many types of cancer including breast \[[@B28]\], oral squamous cell carcinoma \[[@B29]\], and hepatocellular carcinoma \[[@B30]\]. However, there are no data available on the expression and the diagnostic or prognostic relevance of MAGED4B in CCA and BBTDs. KIAA0321 is a zinc finger FYVE domain-containing protein, which mediates binding of these proteins to membrane lipids and may be involved in the abscission step of cytokinesis. However, the relevance of this protein and cancer development is yet to be elucidated \[[@B31]\]. RBAK is a member of a known family of transcriptional repressors that contain zinc fingers of the Kruppel type, which interacts with the tumor suppressor retinoblastoma 1. It has been shown that RBAK is expressed ectopically in human fibroblast cells \[[@B32]\]. Since fibroblasts in the stroma of desmoplastic cancers provide optimal microenvironment for CCA progression and they usually become susceptible for apoptosis \[[@B33]\], it would therefore be possible that overexpression of serum RBAK in CCA patients may be from apoptogenic cancer-associated fibroblasts. UPF3B has been reported to be overexpressed in the patients with alcoholic hepatitis \[[@B34]\], but there is currently no link on UPF3B and cancer yet.

In conclusion we identified proteins in the serum that can potentially discriminate patients with CCA from BBTD individuals through proteomic approach using highly stringent analysis with cross-validation. These proteins will be clinically useful to prevent misdiagnosis between CCA and BBTD as they have similar clinical symptoms. Further independent validation of these biomarkers is certainly required using greater numbers of samples from patients with CCA and a wider range of BBTD conditions to test its robustness and obtain the ones with the greatest diagnostic power for differentiating patients with CCA from BBTD controls.
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![Schematic diagram of the experimental workflow. Serum samples were collected from 17 BBTD patients and 19 CCA patients, which were then subjected to routine ELISA for CEA and CA19-9. Purified proteins from these samples were then separated by SDS-PAGE. After migration, entire lanes were divided into 5 sections, which were excised into slices and treated with in-gel digestion. The resulting tryptic peptides were subjected to reverse-phase LC-MS/MS, from which the mass spectrometric results were then analyzed for protein identification and quantification. The relative quantitation ratios were subjected to statistical analyses and 6-fold cross-validation to retrieve the DE proteins between BBTDs and CCA.](DM2015-105358.001){#fig1}

![An overview of the DE proteins between BBTDs and CCA. (a) Volcano plots on log~2~ fold change and probability values between BBTDs and CCA cases. Red dots correspond to the identified DE proteins that were cut off at *P* \< 0.01. (b) Principle component analysis for DE proteins. Three-dimensional scatter plot represents two clusters of BBTDs and CCA cases based on the DE proteins. Each dot represents a patient with either BBTDs or CCA, as indicated. (c) A hierarchical clustering analysis was carried out on the basis of the expression pattern. The DE proteins were linked together according to their expression (dendrogram on left). BBTD and CCA patients were also clustered (dendrogram on top). The protein-expression intensities were standardized between −3.0 (green) and 3.0 (red).](DM2015-105358.002){#fig2}

![Distribution of DE proteins between BBTDs and CCA according to PANTHER protein classes. The bar chart shows the number of DE proteins in each functional class.](DM2015-105358.003){#fig3}

![Visualization of protein interaction networks of the DE proteins. Inputting all DE proteins into STRING yielded a network visualizing linkages. The network nodes are proteins, whereas the edges represent the functional associations. Different line colors of edges represent different types of evidence for the association, as indicated in the figure.](DM2015-105358.004){#fig4}

![Comparison of the top five differentially expressed proteins between BBTDs and CCA. Normalized log~2~-transformed data were used to create box plots, in which the horizontal lines of each box correspond to the first, second, and third quartiles (25%, 50%, and 75%, resp.) and the whiskers correspond to the maximum and minimum values.](DM2015-105358.005){#fig5}

###### 

Clinical characteristics of patients with benign biliary tract diseases (BBTDs) and cholangiocarcinoma (CCA) in this study.

  Characteristics      BBTDs            CCA              *P* values
  -------------------- ---------------- ---------------- ------------
  Number of patients   17               19               ---
  Sex                                                     
   (Male : female)     10 : 7           10 : 9           0.085
  Age (years)                                             
   Mean ± S.D.         52.6 ± 13        60.9 ± 13        0.285
  CEA (U/mL)                                              
   Median              8.70             9.87             0.711
   (Min--max)          (0.62--118.30)   (1.47--410.40)   
  CA19-9 (ng/mL)                                          
   Median              48.03            4355.50          0.015
    (Min--max)         (0.60--10000)    (0.60--10000)    

###### 

A list of differentially expressed serum proteins between CCA and BBTDs. The protein expression measurements were averaged and represented as log~2~-transformed intensity values with standard deviation. The *P* values are also indicated.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Protein names                                                          ID details                                                                                                        GI accession   CCA\          BBTD\         *P* values
                                                                                                                                                                                                          mean ± SD     mean ± SD     
  ---------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------- -------------- ------------- ------------- ------------
  CCA \> BBTD                                                                                                                                                                                                                          

   ABHD11                                                                Alpha/beta hydrolase domain-containing protein 11                                                                 23200008       1.20 ± 0.4    0.82 ± 0.3    0.002

   ---                                                                   Antioxidized LDL immunoglobulin light chain variable region                                                       62868476       0.88 ± 0.3    0.55 ± 0.3    0.004

   ---                                                                   Chain L, crystal structure of the Fab fragment of nimotuzumab. An antiepidermal growth factor receptor antibody   255311843      1.93 ± 0.2    1.72 ± 0.3    0.010

   ---                                                                   Complement factor H                                                                                               758073         −0.86 ± 0.3   −1.51 ± 0.5   0.001

   COG7                                                                  Conserved oligomeric Golgi complex subunit 7                                                                      23957690       −0.50 ± 0.4   −1.23 ± 0.5   \<0.001

   DHDDS                                                                 Dehydrodolichyl diphosphate synthase                                                                              13177736       0.14 ± 0.6    −0.61 ± 0.5   0.005

   MLH1                                                                  DNA mismatch repair protein                                                                                       4557757        −0.49 ± 0.5   −1.00 ± 0.5   0.004

   EIF3J                                                                 Eukaryotic translation initiation factor 3 subunit J                                                              83281438       2.40 ± 0.4    1.95 ± 0.4    0.002

   FAM19A5                                                               FAM19A5 protein                                                                                                   71052198       0.98 ± 0.3    −0.69 ± 0.7   \<0.001

   HBZ                                                                   Hemoglobin subunite zeta                                                                                          4885397        −0.23 ± 0.3   −0.78 ± 0.4   0.001

   V4-34                                                                 IgG                                                                                                               2632200        0.54 ± 0.4    0.20 ± 0.2    0.001

   ---                                                                   Immunoglobulin heavy chain variable region                                                                        37694587       1.46 ± 0.4    0.93 ± 0.5    0.003

   IGK                                                                   Immunoglobulin kappa light chain VLJ region                                                                       21669309       1.98 ± 0.3    1.68 ± 0.1    \<0.001

   IL16                                                                  Interleukin 16                                                                                                    119619506      0.15 ± 0.4    −0.36 ± 0.6   0.008

   KIAA0321                                                              KIAA0321 protein                                                                                                  2224583        −0.25 ± 0.8   −1.70 ± 0.9   0.002

   KIAA0612                                                              KIAA0612 protein                                                                                                  34327964       −1.17 ± 0.4   −1.76 ± 0.5   0.006

   KIAA0896                                                              KIAA0896 protein                                                                                                  71891755       0.18 ± 0.6    −0.50 ± 0.6   0.003

   MAGED4B                                                               Melanoma-associated antigen D4                                                                                    29337296       0.33 ± 0.3    −1.17 ± 0.9   0.002

   NXF3                                                                  Nuclear RNA export factor 3                                                                                       11545757       0.59 ± 0.4    −0.29 ± 0.5   \<0.001

   PAXBP1                                                                PAX3- and PAX7-binding protein 1                                                                                  22035565       0.64 ± 0.1    0.39 ± 0.2    0.001

   LOC390791                                                             Peptidyl-prolyl cis-trans isomerase A-like                                                                        310113085      −0.50 ± 0.3   −1.24 ± 0.4   0.002

   PLEKHO2                                                               Pleckstrin homology domain-containing family O member 2                                                           33457316       −0.29 ± 0.4   −0.91 ± 0.4   0.001

   PLEKHM2                                                               PLEKHM2 protein                                                                                                   26251859       −0.46 ± 0.4   −1.06 ± 0.5   0.002

   RBAK                                                                  RB-associated KRAB zinc finger protein                                                                            13430850       0.17 ± 0.5    −0.96 ± 0.7   \<0.001

   PTPRG                                                                 Receptor tyrosine phosphatase gamma                                                                               1263069        0.90 ± 0.3    0.54 ± 0.2    \<0.001

   RPS10                                                                 Ribosomal protein S10                                                                                             3088338        0.99 ± 0.2    0.67 ± 0.1    \<0.001

   NOB1                                                                  RNA-binding protein NOB1                                                                                          7661532        −0.81 ± 0.4   −1.26 ± 0.4   0.002

   VAT1                                                                  Synaptic vesicle membrane protein VAT-1                                                                           18379349       0.57 ± 0.4    0.15 ± 0.3    0.003

   TRAC-1                                                                T3 receptor-associating cofactor-1                                                                                1911770        0.12 ± 0.3    −0.28 ± 0.2   \<0.001

   ---                                                                   Unnamed protein product                                                                                           10433849       1.67 ± 0.5    0.77 ± 0.3    \<0.001

   ---                                                                   Unnamed protein product                                                                                           21752201       0.27 ± 0.2    −0.07 ± 0.3   0.001

  CCA \< BBTD                                                                                                                                                                                                                          

   GCAT                                                                  2-Amino-3-ketobutyrate coenzyme A ligase                                                                          7657118        −1.62 ± 0.5   −1.17 ± 0.3   0.002

   ALB                                                                   Albumin                                                                                                           119626083      1.05 ± 0.3    1.45 ± 0.3    \<0.001

   SERPINA1                                                              Alpha-1-antitrypsin                                                                                               1703025        0.84 ± 0.4    1.24 ± 0.3    \<0.001

   A2M                                                                   Alpha-2-macroglobulin                                                                                             177872         −0.04 ± 0.4   0.52 ± 0.3    \<0.001

   AGT                                                                   Angiotensinogen                                                                                                   4261988        0.09 ± 0.6    0.79 ± 0.2    \<0.001

   apo AII                                                               Apolipoprotein                                                                                                    671882         0.04 ± 0.3    0.31 ± 0.2    0.003

   APOB                                                                  Apolipoprotein B-100                                                                                              105990532      −1.67 ± 0.4   −0.86 ± 0.5   \<0.001

   ARID5B                                                                AT-rich interactive domain-containing protein 5B                                                                  74136549       0.08 ± 0.5    0.71 ± 0.7    0.006

   BAZ2                                                                  BWSCR2 associated zinc-finger protein BAZ2                                                                        6002480        −0.50 ± 0.9   0.23 ± 0.3    0.005

   C1orf87                                                               C1orf87 protein                                                                                                   27503780       −0.91 ± 0.4   −0.49 ± 0.3   0.001

   PDEA                                                                  cGMP phosphodiesterase                                                                                            2366987        0.11 ± 0.4    0.73 ± 0.3    \<0.001

  Chain D, The Nucleosome Containing A Testis-Specific Histone Variant   296863399                                                                                                         −2.56 ± 0.4    −2.04 ± 0.5   0.002         

   C4A                                                                   Complement C4-A                                                                                                   476007827      −0.81 ± 0.7   −0.02 ± 0.3   \<0.001

   DCAF15                                                                DDB1- and CUL4-associated factor 15                                                                               78486540       0.87 ± 0.4    1.31 ± 0.2    \<0.001

   FN1                                                                   Fibronectin 1                                                                                                     53791223       −0.98 ± 0.5   −0.29 ± 0.4   \<0.001

   FLJ00044                                                              FLJ00044 protein                                                                                                  10440418       −1.02 ± 0.4   −0.59 ± 0.2   0.004

   FLJ16008                                                              FLJ16008 protein, isoform CRA_b                                                                                   119615716      1.79 ± 0.1    1.94 ± 0.2    0.006

   GNG5                                                                  Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-5                                                 4885287        0.94 ± 0.3    1.24 ± 0.1    \<0.001

   hCG_1817987                                                           hCG1817987                                                                                                        119612015      −0.09 ± 0.3   0.36 ± 0.3    \<0.001

   hCG_1981701                                                           hCG1981701                                                                                                        119572460      −1.14 ± 0.5   −0.52 ± 0.5   0.002

   hCG_2008076                                                           hCG2008076                                                                                                        119592316      0.05 ± 0.4    0.42 ± 0.2    0.012

   hCG_2008267                                                           hCG2008267                                                                                                        119592800      −0.07 ± 0.4   0.35 ± 0.2    0.001

   hCG_201157                                                            hCG201157                                                                                                         119576573      0.64 ± 0.3    0.89 ± 0.3    0.009

   hCG_2020343                                                           hCG2020343                                                                                                        119629275      −0.95 ± 0.4   −0.27 ± 0.4   \<0.001

   ---                                                                   Hypothetical protein                                                                                              12224988       −1.46 ± 0.5   −0.90 ± 0.4   \<0.001

   FLJ22688                                                              Hypothetical protein FLJ22688, isoform CRA_b                                                                      119572924      −0.93 ± 0.6   −0.17 ± 0.4   \<0.001

   LOC286076                                                             Hypothetical protein LOC286076                                                                                    119602615      1.19 ± 0.4    1.52 ± 0.2    0.003

   IgA1                                                                  Ig Aalpha1 Bur                                                                                                    223099         1.84 ± 0.6    2.28 ± 0.3    0.006

  Immunoglobulin heavy chain variable region                             37694587                                                                                                          1.48 ± 0.3     1.70 ± 0.1    0.007         

   ITIH1                                                                 Interalpha (globulin) inhibitor H1                                                                                825681         −0.74 ± 0.4   0.08 ± 0.6    0.001

   ITIH2                                                                 Interalpha (globulin) inhibitor H2                                                                                119606784      −1.44 ± 0.5   −0.54 ± 0.4   \<0.001

   KRT1                                                                  Keratin 1                                                                                                         11935049       −1.12 ± 0.3   −0.56 ± 0.4   \<0.001

   KRT10                                                                 Keratin-10                                                                                                        307086         −2.40 ± 0.5   −1.50 ± 0.6   \<0.001

   KIAA0366                                                              KIAA0366 protein                                                                                                  2224673        −1.45 ± 0.4   −0.61 ± 0.6   \<0.001

   KIAA0920                                                              KIAA0920 protein                                                                                                  40788986       1.05 ± 0.3    1.37 ± 0.2    \<0.001

   KIAA1234                                                              KIAA1234 protein                                                                                                  6330736        −0.70 ± 0.4   −0.38 ± 0.3   0.007

   KIAA1529                                                              KIAA1529 protein                                                                                                  7959325        1.33 ± 0.3    2.38 ± 0.4    \<0.001

   MAGEB2                                                                Melanoma-associated antigen B2                                                                                    222418639      −0.48 ± 0.3   −0.07 ± 0.4   0.001

   MTDH                                                                  Metadherin                                                                                                        119612168      −0.45 ± 0.3   −0.09 ± 0.3   \<0.001

   MUC16                                                                 Mucin-16                                                                                                          74716283       −0.49 ± 0.5   0.41 ± 0.4    \<0.001

   MYOT                                                                  Myotilin                                                                                                          5803106        −0.41 ± 0.5   0.30 ± 0.3    \<0.001

   NPTX1                                                                 Neuronal pentraxin 1                                                                                              1438954        1.51 ± 0.3    1.74 ± 0.2    0.010

   PLG                                                                   Plasminogen                                                                                                       38051823       1.67 ± 0.3    2.17 ± 0.4    \<0.001

   GALNT2                                                                Polypeptide N-acetylgalactosaminyltransferase 2                                                                   4758412        −0.99 ± 0.3   −0.50 ± 0.3   \<0.001

   FAM83E                                                                Protein FAM83E                                                                                                    153251792      0.70 ± 0.5    1.33 ± 0.3    0.006

   LOC100131107                                                          Putative UPF0607 protein ENSP00000383783                                                                          239741331      1.03 ± 0.7    2.07 ± 0.7    0.002

   RAB-R                                                                 RAB-R protein                                                                                                     4102709        −0.83 ± 0.4   −0.05 ± 0.3   0.002

   UPF3B                                                                 Regulator of nonsense transcripts 3B                                                                              18375528       −2.17 ± 0.5   −0.99 ± 0.6   \<0.001

   RIMBP3                                                                RIMBP3 protein                                                                                                    71052030       0.07 ± 0.4    0.69 ± 0.4    \<0.001

  Suppressor of cytokine signaling 3                                     54695958                                                                                                          0.85 ± 0.4     1.23 ± 0.2    0.004         

  Testis specific kinase-1                                               21886788                                                                                                          −1.65 ± 0.3    −1.07 ± 0.7   0.005         

   TTC34                                                                 Tetratricopeptide repeat protein 34                                                                               239741018      −0.54 ± 0.5   0.34 ± 0.3    \<0.001

   TPO                                                                   Thyroid peroxidase                                                                                                4680721        0.69 ± 0.4    1.15 ± 0.2    \<0.001

   ---                                                                   Ubiquitously transcribed tetratricopeptide repeat protein Y-linked transcript                                     148733192      −1.43 ± 0.4   −0.88 ± 0.5   0.001

   ---                                                                   Unnamed protein product                                                                                           34531956       0.84 ± 0.3    1.17 ± 0.2    \<0.001

   ---                                                                   Unnamed protein product                                                                                           10435479       0.76 ± 0.4    1.15 ± 0.3    0.003

   ---                                                                   Unnamed protein product                                                                                           194384842      1.24 ± 0.3    1.67 ± 0.2    \<0.001

   ---                                                                   Unnamed protein product                                                                                           22760231       1.14 ± 0.5    1.77 ± 0.3    \<0.001

   ---                                                                   Unnamed protein product                                                                                           194381130      −2.08 ± 0.4   −1.34 ± 0.5   \<0.001

   DBP                                                                   Vitamin D-binding protein                                                                                         455970         0.88 ± 0.5    1.30 ± 0.3    0.007

   ZNF410                                                                Zinc finger protein 410                                                                                           119601547      −0.27 ± 0.4   0.46 ± 0.3    \<0.001

   ZnF_RBZ                                                               ZIS1                                                                                                              4191327        0.03 ± 0.4    0.55 ± 0.4    0.001
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

[^1]: Academic Editor: Joy Scaria
